C Marth
Overview
Explore the profile of C Marth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
213
Citations
2835
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harter P, Marth C, Mouret-Reynier M, Cropet C, Lorusso D, Guerra-Alia E, et al.
Ann Oncol
. 2024 Nov;
36(2):185-196.
PMID: 39528049
Background: The use of first-line poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is increasing in advanced ovarian cancer. Understanding the efficacy of first subsequent therapy (FST) in patients experiencing disease progression...
2.
Ebner C, Frosch A, Leitner K, Soucek R, Marth C, Zeimet A
Gynecol Oncol Rep
. 2024 Jul;
54:101442.
PMID: 39040939
Carcinosarcomas are high-grade endometrial cancers which enclose mesenchymal and epithelial differentiated components. The vast majority of these cancers belong to the p53 abnormal molecular subgroup and usually come with an...
3.
Ledermann J, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, et al.
Ann Oncol
. 2024 Feb;
35(3):248-266.
PMID: 38307807
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June...
4.
Hasson S, Ray-Coquard I, Marth C, Harter P
ESMO Open
. 2023 Nov;
8(6):102052.
PMID: 37922687
No abstract available.
5.
Lehmann M, Hosa H, Bartl T, Tsibulak I, Polterauer S, Potsch N, et al.
Gynecol Oncol Rep
. 2023 Aug;
49:101259.
PMID: 37636493
Introduction: Gestational trophoblastic neoplasia (GTN) including choriocarcinoma (CC) frequently requires multi-agent chemotherapy to achieve cure. In chemotherapy-resistant GTN, immunotherapy with the checkpoint inhibitors pembrolizumab, avelumab and camrelizumab are potential new...
6.
Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonzalez-Martin A, Marth C, et al.
Ann Oncol
. 2023 May;
34(8):681-692.
PMID: 37211045
Background: In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly diagnosed advanced ovarian cancer patients in clinical response after first-line platinum-based...
7.
Oaknin A, Bosse T, Creutzberg C, Giornelli G, Harter P, Joly F, et al.
Ann Oncol
. 2022 Jun;
33(9):860-877.
PMID: 35690222
No abstract available.
8.
Jerusalem G, Farah S, Courtois A, Chirgwin J, Aebi S, Karlsson P, et al.
Ann Oncol
. 2021 Aug;
32(10):1256-1266.
PMID: 34384882
Background: Late recurrences in postmenopausal women with hormone receptor-positive breast cancers remain an important challenge. Avoidance or delayed development of resistance represents the main objective in extended endocrine therapy (ET)....
9.
Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N
Ann Oncol
. 2018 May;
29(Suppl 4):iv262.
PMID: 29741577
No abstract available.
10.
Dueckelmann A, Fink D, Harter P, Heinzelmann V, Marth C, Mueller M, et al.
Arch Gynecol Obstet
. 2018 Feb;
297(4):847.
PMID: 29445924
The title of the article has been published incorrectly. The correct title is given below.